NHS pilots new genetic testing service for cancer patients

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f3323 (Published 21 May 2013)
Cite this as: BMJ 2013;346:f3323

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Krishna Chinthapalli
  1. 1BMJ

A new programme to develop genetic testing in patients with cancer will be piloted in London within the next six months.

The Mainstreaming Cancer Genetics programme has been launched with £2.7m (€3.2m; $4.1m) funding from the Wellcome Trust and will use next generation gene sequencing technology to test patients with cancer. The test, called the TruSight cancer targeted microarray panel, costs “a few hundred pounds” per patient and will analyse 97 cancer predisposition genes for mutations.

Currently no test is available for over half these genes, and the microarray panel could also replace testing for mutations in single genes, such as BRCA1. It was a BRCA1 gene mutation …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL